Arteriosclerosis Thrombosis and Vascular Biology · 2005 · 76 citations · 23 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyInflammationNeuropharmacologyAnti-inflammatory PharmacologyCerebrovascular DiseaseNeuroinflammationNeuroprotectionStrokeStroke PharmacotherapyCerebrovascular InflammationHydrophilicity EffectsHydrophobicityMonocyte Chemoattractant Protein-1Neuroinflammation In StrokeRodent Cerebral IschemiaSalt LoadingStroke Neuroprotection
OBJECTIVE: Brain abnormalities, preceded by a systemic inflammation, develop in spontaneously hypertensive stroke-prone rats (SHRSP). In this model, we investigated whether the hydrophilic statin, rosuvastatin, influences the development of inflammation associated with brain abnormalities. Because differences in hydrophilicity/hydrophobicity contribute to the differences in statin pharmacology, we also evaluated the effects of simvastatin, a lipophilic molecule METHODS AND RESULTS: SHRSP, fed a high-salt diet, were treated long-term with vehicle or rosuvastatin (1 and 10 mg/kg per day). Brain abnormalities developed after 40+/-5 days and after 60+/-5 days of salt loading, in vehicle-treated and in rosuvastatin-treated (1 mg/kg per day) SHRSP, respectively. After 100 days of treatment, no damage was detectable in 30% of the rats treated with the highest dose of the drug. In comparison with vehicle-treated SHRSP, rosuvastatin treatment attenuated the transcription of monocyte chemoattractant protein-1, transforming growth factor-beta1, IL-1beta, and tumor necrosis factor-alpha in the kidney, and of P-selectin in brain vessels and increased the transcription of endothelial nitric oxide synthase mRNA in the aorta. Urinary excretion of acute-phase proteins increased with time in vehicle-treated animals but remained negligible in drug-treated animals. These effects are independent of changes in physiological parameters. Treatment of SHRSP with simvastatin (2 to 20 mg/kg per day) did not exert any protective effect. CONCLUSIONS: Rosuvastatin attenuates inflammatory processes associated with cerebrovascular disease.
23
Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
Paul M. Ridker, Nader Rifai, Marc A. Pfeffer et al. · Circulation · 1999 · 1.5K citations · Full text
C-Reactive Protein and Outcome After Ischemic Stroke
Keith W. Muir, Christopher J. Weir, W H Alwan et al. · Stroke · 1999 · 319 citations
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Ricardo Rocha, Praveen Chander, Andrea Zuckerman et al. · Hypertension · 1999 · 311 citations
Medicine, Cardiology, Pharmacology +17
K. O. Pietlla, Aimo Harmoinen, J. Jokiniitty et al. · European Heart Journal · 1996 · 263 citations · Full text
Timothy J. Stalker, Allan M. Lefer, Rosario Scalia · British Journal of Pharmacology · 2001 · 202 citations · Full text